950271-98-4

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Chloro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester is used as a reactant for the synthesis of 1,5and 1,4-disubstituted 1,2,3-triazoles, which are important structural motifs in pharmaceutical chemistry. These triazoles can be found in a variety of drug candidates and have been shown to possess diverse biological activities, including antimicrobial, anticancer, and antiviral properties.
Used in Chemical Research:
In the field of chemical research, 1-(3-Chloro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester serves as a key intermediate for the development of new synthetic methods and the exploration of novel chemical reactions. Its unique structure allows for the investigation of its reactivity and the potential for the formation of new triazole-containing compounds with interesting properties.
Used in Material Science:
1-(3-Chloro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester can also be utilized in material science for the development of new materials with specific properties. The triazole ring is known for its stability and ability to form coordination complexes, which can be exploited in the design of materials with applications in catalysis, sensors, and other areas.

Upstream product

• 108-42-9 3-chloro-aniline 
• 623-47-2 propynoic acid ethyl ester 
• 3296-06-8 1-azido-3-chlorobenzene 

Downstream Products

• 944901-58-0 1-(3-chlorophenyl)-1H-1,2,3-triazole-4-carboxylic acid 

Relevant academic research and scientific papers

Alkyl Propiolates Participated [3+2] Annulation for the Switchable Synthesis of 1,5- and 1,4-Disubstituted 1,2,3-Triazoles Containing Ester Side Chain

By means of a featured enamine activation, the alkyl propiolates have been successfully employed in the [3+2] annulation for the synthesis of 1,2,3-triazoles. The synthesis of both 1,4- as well as the hardly available 1,5-disubstituted 1,2,3-triazoles can be selectively accessed by using tosyl azide and tosyl hydrazine as nitrogen source, respectively.

TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.